Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Head & Neck 2Gynecologic 2Genitourinary 2Breast 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Dermatologic 1CNS 1

Conditions

Ovarian Neoplasms 27Fallopian Tube Neoplasms 24Uterine Cervical Neoplasms 7Brenner Tumor 6Endometrial Neoplasms 5Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Melanoma 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Uterine Neoplasms 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Lung Neoplasms 2Esophageal Neoplasms 2Endometrial Adenocarcinoma 2Cervical Adenocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Stomach Neoplasms 1Somatostatinoma 1Sertoli-Leydig Cell Tumor 1Sarcoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrence 1

Interventions

pembrolizumab 24Paclitaxel 7Docetaxel 7Cyclophosphamide 7Carboplatin 7fludarabine 6Taxes 6Nivolumab 6Trastuzumab 5Magnetic Resonance Spectroscopy 5atezolizumab 4Specimen Handling 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Gemcitabine 4Fluorouracil 4Cisplatin 4tisotumab vedotin 3fludarabine phosphate 3Radiation 3Oxaliplatin 3Leucovorin 3Irinotecan 3Ipilimumab 3Gene Expression Profiling 3Drug Therapy 3Counseling 3Albumin-Bound Paclitaxel 3zimberelimab 2ulixertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Immunoglobulin G × Gynecologic × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04424641 2023-07-25

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

Genmab

Phase 1/2 Terminated
48 enrolled 20 charts
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Prostatic Neoplasms, Uterine Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡